Company Overview and News

2
Markets Live: ASX closes at lowest value since June

2018-09-10 theage.com.au
Below is William's market wrap. I will be back editing tomorrow. CSL is going ex-dividend tomorrow by 127.8 cents, and NAB's business conditions indicator will be out in the morning.
BGCHY RIO BLT RIO MAYNF OGFGY OISHF BEPTF RTPPF MYX RTNTF INCZY OSH PRY OISHY BHPBF BGA WTCHF BCHEY MYPHY PHCRY BPT PTM BHP RIO BBL PHCRF BHP OGFGF BHPLF ICPVF IPL ORG

2
Markets Live: ASX closes at lowest value since June

2018-09-10 smh.com.au
Below is William's market wrap. I will be back editing tomorrow. CSL is going ex-dividend tomorrow by 127.8 cents, and NAB's business conditions indicator will be out in the morning.
BGCHY RIO BLT RIO MAYNF OGFGY OISHF BEPTF RTPPF MYX RTNTF INCZY OSH PRY OISHY BHPBF BGA WTCHF BCHEY MYPHY PHCRY BPT PTM BHP RIO BBL PHCRF BHP OGFGF BHPLF ICPVF IPL ORG

2
Miners lift ASX as commodity prices rise

2018-08-27 theage.com.au
The Australian sharemarket recorded its best performance in eight sessions as investors looked beyond the political uncertainty that plagued the market last week.
PLS PILBF RIO BLT RIO BHPBF GEM MALRY MIN OGFGY RSG PTM RTPPF RMGGY BHP RIO RMGGF RTNTF BBL BHP MALRF OGFGF BHPLF ORG

2
Miners lift ASX as commodity prices rise

2018-08-27 smh.com.au
The Australian sharemarket recorded its best performance in eight sessions as investors looked beyond the political uncertainty that plagued the market last week.
PLS PILBF RIO BLT RIO BHPBF GEM MALRY MIN OGFGY RSG PTM RTPPF RMGGY BHP RIO RMGGF RTNTF BBL BHP MALRF OGFGF BHPLF ORG

 
Investors seek answers to global headwinds and debt, says Weiss

2018-08-09 theage.com.au
Geopolitical tension, soaring debt and the withdrawal of support by central banks are top of mind issues for investors, according to high profile businessman and director Gary Weiss.
PTM ARA

 
Investors seek answers to global headwinds and debt, says Weiss

2018-08-09 smh.com.au
Geopolitical tension, soaring debt and the withdrawal of support by central banks are top of mind issues for investors, according to high profile businessman and director Gary Weiss.
PTM ARA

 
ASX falls on financial heavyweights as tariff deadline looms

2018-07-04 theage.com.au
The Australian sharemarket has wiped most of its gains from the previous session, falling heavily on the losses made by the financial heavyweights.
ILKAF ILU RSG PTM RMGGY RMGGF MS ILKAY

 
ASX falls on financial heavyweights as tariff deadline looms

2018-07-04 smh.com.au
The Australian sharemarket has wiped most of its gains from the previous session, falling heavily on the losses made by the financial heavyweights.
ILKAF ILU RSG PTM RMGGY RMGGF MS ILKAY

 
Immutep Ltd raises $6.8 million to fund immuno-oncology clinical development program

2018-03-11 proactiveinvestors.com.au
Immutep Ltd (ASX:IMM) has raised about $6.8 million through the placement of more than 326 million new fully paid ordinary shares at an issue price of 2.1 cents.
PTM AEF AHCLF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:PTM / PLATINUM ASSET MANAGEMENT LIMITED on message board site Silicon Investor.

PTM: Tier 1 PTM: Tier 1 PTM: Tier 1 PTM News Release PTM News Release PTM News Release
Imperial Petroleum ( BB:IPTM ) Imperial Petroleum ( BB:IPTM ) Imperial Petroleum ( BB:IPTM )